# Alios Biopharma Inc. clinical trials: 21 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 21 trials with Alios Biopharma Inc. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Alios Biopharma Inc.: 21 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/alios-biopharma-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 21
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 21 newest of 21, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| February 20, 2018 | NCT03439488 | A Study of Orally Administered JNJ-440 to Evaluate the Safety, Tolerability, and Pharmacokinetics After Single Ascending Doses Including... | Alios Biopharma Inc. | Phase 1 | Completed | Chronic Hepatitis B | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03439488) |
| January 26, 2018 | NCT03411421 | A Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Dosing Regimens of AL-794 in Healthy Volunteers | Alios Biopharma Inc. | Phase 1 | Terminated | Healthy | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03411421) |
| September 18, 2017 | NCT03285620 | A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants | Alios Biopharma Inc. | Phase 1 | Completed | Hepatitis B | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03285620) |
| August 18, 2017 | NCT03253471 | A First in Human Study of AL-611 in Healthy Volunteers and Patients With Hepatitis C Virus Infection | Alios Biopharma Inc. | Phase 1 | Terminated | Hepatitis C | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03253471) |
| April 24, 2017 | NCT03125213 | A Study Evaluating AL-3778 in Combination With Peginterferon Alpha-2a in Chronic Hepatitis B Subjects | Alios Biopharma Inc. | Phase 2 | Withdrawn | Hepatitis B, Chronic | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03125213) |
| January 26, 2017 | NCT03032536 | Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in... | Alios Biopharma Inc. | Phase 1 | Terminated | Hepatitis B, Chronic Hepatitis B, Viral Hepatitis B | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03032536) |
| September 5, 2016 | NCT02888327 | A Drug-Drug Interaction Study to Evaluate the Effect of AL-794 on the Pharmacokinetics of Oseltamivir and JNJ-63623872 | Alios Biopharma Inc. | Phase 1 | Completed | Influenza in Humans | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02888327) |
| August 24, 2016 | NCT02877160 | A Study to Assess the PK of AL-794 Formulations in Healthy Subjects | Alios Biopharma Inc. | Phase 1 | Completed | Influenza | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02877160) |
| February 4, 2016 | NCT02673476 | A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus | Alios Biopharma Inc. | Phase 2 | Completed | Respiratory Syncytial Virus Infections | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02673476) |
| October 28, 2015 | NCT02588521 | A Study of AL-794 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses, and the Antiviral Activity of... | Alios Biopharma Inc. | Phase 1 | Completed | Influenza | 152 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02588521) |
| October 7, 2015 | NCT02569710 | A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir | Alios Biopharma Inc. | Phase 2 | Completed | Chronic Hepatitis C | 161 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02569710) |
| July 31, 2015 | NCT02512562 | A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers | Alios Biopharma Inc. | Phase 1 | Completed | Chronic Hepatitis C | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02512562) |
| July 29, 2015 | NCT02510248 | First in Human Study of AL-704; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C | Alios Biopharma Inc. | Phase 1 | Terminated | Chronic Hepatitits C | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02510248) |
| January 15, 2015 | NCT02339207 | First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1 | Alios Biopharma Inc. | Phase 1 | Completed | Chronic Hepatitis C | 112 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02339207) |
| September 4, 2014 | NCT02231671 | A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176 | Alios Biopharma Inc. | Phase 1 | Completed | Respiratory Syncytial Virus Infections | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02231671) |
| July 29, 2014 | NCT02202356 | A Study of ALS-008176 in Infants Hospitalized With RSV | Alios Biopharma Inc. | Phase 1 | Completed | Respiratory Syncytial Virus Infections | 183 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02202356) |
| March 21, 2014 | NCT02094365 | A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model | Alios Biopharma Inc. | Phase 2 | Completed | Respiratory Syncytial Virus Infections | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02094365) |
| July 24, 2013 | NCT01906164 | Study of Single and Multiple Doses of ALS-008176 in Healthy Volunteers | Alios Biopharma Inc. | Phase 1 | Completed | Respiratory Syncytial Virus Infections | 101 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01906164) |
| February 13, 2013 | NCT01790100 | A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects... | Alios Biopharma Inc. | Phase 2 | Completed | Chronic Hepatitis C | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01790100) |
| May 3, 2012 | NCT01590407 | First in Human Study of ALS-002200; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1 | Alios Biopharma Inc. | Phase 1 | Completed | Hepatitis C, Chronic | 71 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01590407) |
| March 14, 2012 | NCT01554085 | First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1 | Alios Biopharma Inc. | Phase 1 | Terminated | Hepatitis C, Chronic | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01554085) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 16 |
| Phase 2 | 5 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 15 |
| Terminated | 5 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hepatitis C, Chronic | 6 |
| Respiratory Syncytial Virus Infections | 5 |
| Hepatitis B, Chronic | 3 |
| Hepatitis B | 3 |
| Influenza, Human | 3 |
| Hepatitis C | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Coworking spaces in the United States](https://specstream.ai/data/businesses/coworking-spaces/united-states)
- [General dentistry practices in the United States](https://specstream.ai/data/businesses/general-dentistry-practices/united-states)
- [Machine shops in the United States](https://specstream.ai/data/businesses/machine-shops/united-states)
- [Pressure washing companies in the United States](https://specstream.ai/data/businesses/pressure-washing-companies/united-states)
- [Test preparation centers in the United States](https://specstream.ai/data/businesses/test-preparation-centers/united-states)
- [Automation companies in the United States](https://specstream.ai/data/businesses/automation-companies/united-states)
